NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Telix Pharmaceuticals Limited TLX
4 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$803.8M
▲ 55.6% vs FY2024
EPS · FY25
$-0.02
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-0.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 803.8M
Revenue, FY2025 · full 4-year series below
Revenue
Net income
The company lost 1 cents on every revenue dollar this year.
Per share
USD -0.02
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin3.7%
Net margin-0.9%
Return on assets-0.7%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+71.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.2B
total assets, end of FY2025
Total assetsUSD 1.2B
CashUSD 141.9M
Gross debtUSD 405.0M
Net debtUSD 263.2M
Current ratio1.43×
History
4 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
Revenue $B
0.8
0.5
0.3
0.2
Operating income $B
0.0
0.1
0.0
−0.1
EBITDA $B
0.1
0.1
0.0
−0.1
Income tax $B
0.0
0.0
−0.0
0.0
Net income $B
−0.0
0.0
0.0
−0.1
EPS, diluted $
−0.02
0.10
0.01
−33.50
Dividend / sh $
·
·
·
·
Payout %
·
·
·
·
ROE %
·
·
·
·
Shares out B
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
13 of 14
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed